Dr. Lal PathLabs Limited secured near-unanimous shareholder approval for all ten resolutions at its 32nd Annual General Meeting (AGM) held on July 25, 2026, confirming the final dividend of ₹4 per share and leadership continuity. The scrutinizer’s report, filed with the National Stock Exchange of India Limited and BSE Limited under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, revealed that promoters voted in favor of every resolution, while public dissent remained negligible across all proposals.

The meeting, conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM) in compliance with the Companies Act, 2013, saw high participation from institutional investors. Central Depository Services (India) Limited (CDSL) facilitated e-voting, which ran from July 21, 2026, to July 24, 2026, for remote voting, followed by live voting during the AGM. M/s. K.K Singh & Associates served as the Scrutinizer, certifying that the electronic data was maintained securely until the Chairman signed the minutes.

Voting Breakdown by Resolution

Promoter group holdings of 89,162,270 shares represented approximately 53% of the total outstanding equity and voted uniformly in favor of all agenda items. Public institutions and non-institutional shareholders also showed strong support, particularly for financial and governance-related resolutions.

Leadership and Governance Continuity

Shareholders approved the re-appointment of (Hony) Brig Dr Arvind Lal as Executive Chairman for a five-year term commencing April 01, 2027, alongside a revision in his remuneration structure. Similarly, Dr Vandana Lal, Whole-Time Director, received approval for her revised remuneration. Mr. Rajit Mehta was re-appointed as Non-Executive Independent Director for a second five-year term starting July 27, 2026. Mr. Rahul Sharma was re-appointed as Non-Executive Director, with shareholders also consenting to payment of remuneration in the event of ESOP exercises exceeding 50% of total non-executive director pay.

During the discussion on special resolutions involving interested parties, (Hony) Brig Dr Arvind Lal deemed himself interested and entrusted the conduct of proceedings to Mr. Arun Duggal, Lead Independent Director. Statutory Auditors Deloitte Haskins & Sells LLP and Secretarial Auditors Chandrasekaran Associates confirmed no qualifications in their respective reports for FY26.

What the Numbers Show

The unanimous support from the promoter group underscores strong alignment between management and controlling shareholders on strategic direction and compensation structures. While public institutional investors showed slight dissent on the re-appointment of Mr. Rahul Sharma (0.69% against) and Mr. Rajit Mehta (0.34% against), these figures are statistically insignificant relative to the overall vote pool. The near-perfect approval for the dividend declaration and cost auditor ratification indicates broad confidence in the company’s financial stewardship and compliance framework.

Dr. Lal PathLabs Limited has secured a favourable outcome from the Commissioner of Income Tax (Appeals), which allowed its appeal concerning the disallowance of ESOP expenses. The appellate order, dated July 16, 2026, permits the company to claim a deduction of ₹32,66,18,927 on account of ESOP expenses. This decision reverses the position taken in the assessment order dated March 31, 2024, which had originally been contested by the diagnostic company.

The company received the communication on July 17, 2026. The order was passed under section 250 of the Income Tax Act, 1961, following an appeal filed against the earlier assessment. The resolution of this tax dispute removes a potential financial liability, as the deduction has now been formally recognized by the tax authorities.

Details of the Appellate Order

The disclosure was made to the exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The specific details of the order are outlined below:

Vinay Gujral, Company Secretary & Compliance Officer, confirmed that the appeal was decided in the company's favour. The filing noted that there is no quantifiable adverse impact on the financial or operational activities of the listed entity resulting from this order.